Strategies for optimizing antiepileptic drug therapy in elderly people

Pharmacotherapy

Volumn 22, Issue 3 II, 2002, Pages 329-364

  Lackner, Thomas E ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; DEPAKOTE ER; DIAZEPAM; DILANTIN INFATAB; DILANTIN KAPSEAL; ENOXACIN; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; LOXAPINE; METOCLOPRAMIDE; OLANZAPINE; OXCARBAZEPINE; PENICILLIN DERIVATIVE; PHENOBARBITAL; PHENOTHIAZINE DERIVATIVE; PHENYTOIN; PRIMIDONE; QUETIAPINE; TIAGABINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TROVAFLOXACIN; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; ZONISAMIDE;

ANOREXIA; ANTICONVULSANT THERAPY; ATAXIA; BEHAVIOR DISORDER; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CORRELATION ANALYSIS; DEMENTIA; DIPLOPIA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG UTILIZATION; EPILEPSY; GERIATRIC CARE; HEADACHE; HUMAN; HYPOTENSION; LETHARGY; NAUSEA; NEUROPATHY; NURSING HOME; OUTCOMES RESEARCH; PAIN; PHARMACODYNAMICS; PHARMACOKINETICS; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; REVIEW; TREMOR; VERTIGO;

EID: 0036193577     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.5.329.33192     Document Type: Review

References (301)

1. Antiepileptics in elderly patients. Pharmacoepidemiology and pharmacokinetics
2. Antiepileptic drug use in nursing home residents: Effect of age, gender, and co-medication on patterns of use
3. Epidemiology of seizures and epilepsy in elderly patients
4. Adverse drug reaction surveillance in the geriatric population: A review
5. Adverse events related to drugs and drug withdrawal in nursing home residents
6. Risk factors for falls as a cause of hip fracture in women
7. General principles: Use of antiepileptic drugs in children and elderly patients
8. Diphenylhydantoin metabolism, blood levels, and toxicity
9. Seizure disorders: The changes with age
10. An evaluation of antiepileptic drug therapy in nursing facilities
11. Use of antiepileptic drugs in elderly patient populations
12. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy
13. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy
14. A randomized open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy
15. Monotherapy trials of new antiepileptic drugs
16. Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy
17. Gabapentin monotherapy. I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures
18. Gabapentin monotherapy. II. A 26-week, double-blind dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures
19. Pathologic processes in elderly patients and their association with seizures
20. The risk of unprovoked seizures after encephalitis and meningitis
21. Selecting an antidepressant for use in a patient with epilepsy
22. Drug-induced seizures in elderly patients. Causative agents and optimal management
23. Seizure risk associated with psychotropic drugs: Clinical and pharmacokinetic considerations
24. Herbal medicinals. Selected clinical considerations focusing on known or potential drug-herb interactions
25. Epileptic seizures in acute stroke
26. Drug-induced seizures
27. Misleading presentation of epilepsy in elderly people
28. The altered presentation of seizures in elderly patients
29. Drug-induced cognitive impairment in the elderly
30. The first seizure in adult life: Value of clinical features, electroencephalography and computerized tomographic scanning in prediction of seizure recurrence
31. Treatment of epilepsy in elderly patients
32. The prognosis of primary intracerebral tumours presenting with epilepsy: The outcome of medical and surgical management
33. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia
34. Cognitive and adjustmental consequences of seizures and antiepileptic drugs in elderly patients
35. Depressive illness in patients with epilepsy: A review
36. The quality of life of older people with epilepsy: Findings from a UK community study
37. Through a glass darkly: Assessing the quality of care of older people using quality of life measures
38. Psychiatric disorders of epilepsy in the older
39. The cost of epilepsy in the United States: An estimate from population-based clinical and survey data
40. Cost of epilepsy in the United States: A model based on incidence and prognosis
41. Epilepsy in the elderly: Prognosis
42. Prognosis for total control of complex partial and secondary generalized tonic-clonic seizures
43. Effect of age on epilepsy and its treatment: Results from the VA cooperative study
44. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: A randomized comparative monotherapy trial
45. The evaluation and treatment of seizures
46. Epilepsy in elderly patients: A pharmacological perspective
47. Evidence-based medicine and antiepileptic drugs
48. Cognitive adverse effects of antiepileptic drugs. Incidence, mechanisms and therapeutic implications
49. Overflow urinary incontinence due to carbamazepine
50. Incontinence during treatment with gabapentin
51. Adverse reactions to new anticonvulsant drugs
52. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondary generalized tonic-clonic seizures
53. Anticonvulsant therapy in the elderly - A need for placebo controlled trials
54. Monotherapy or polytherapy for epilepsy revisited: A quantitative assessment
55. Two antiepileptic drugs for intractable epilepsy with complex-partial seizures
56. Combination valproate-carbamazepine therapy in partial epilepsies resistant to carbamazepine monotherapy
57. Efficacy and safety of add-on divalproex sodium in the treatment of complex partial seizures
58. The new antiepileptic drugs: A systematic review of their efficacy and tolerability
59. Pharmacologic advantages of antiepileptic drug monotherapy
60. Guidelines for thrombolytic therapy for acute stroke: A statement for healthcare professionals from a special writing group on the stroke council
61. Poststroke seizures in the elderly
62. Guidelines for the management of aneurysmal subarachnoid hemorrhage: A statement for healthcare professionals from a special writing group of the stroke council
63. Randomized study of antiepileptic drug withdrawal in patients in remission
64. When to start and when to stop treatment for seizures
65. Withdrawal of anticonvulsant drugs in patients free of seizures for two years
66. Practice parameter: A guideline for discontinuing antiepileptic drugs in seizure-free patients - Summary statement. Report of the quality standards subcommittee of the American Academy of Neurology
67. Management of acute seizure episodes
68. A comparison of rectal diazepam gel and placebo for acute repetitive seizures
69. Intrarectal diazepam in epileptic adults
70. Intermittent home treatment of status and clusters of seizures
71. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam
72. Implications of altered drug disposition in the elderly: Studies of benzodiazepines
73. Rectal diazepam: Pitfalls of excessive use in refractory epilepsy
74. Fosphenytoin: A novel phenytoin prodrug
75. Epidemiology of status epilepticus
76. Status epilepticus
77. Status epilepticus: Treatment in 2001. New approaches, new medicines
78. Results of a controlled trial of benzodiazepines for the treatment of status epilepticus in the prehospital setting
79. A comparison of four treatments for generalized convulsive status epilepticus
80. Treatment of status epilepticus if first drug fails
81. Management approaches to prolonged seizures and status epilepticus
82. Age and gender related differences in diazepam pharmacokinetics
83. Diazepam kinetics in relation to age and sex
84. Relationship between diazepam dose, plasma level, age, and central nervous system depression
85. Use of injectable valproic acid in status epilepticus: A pilot study
86. Intravenous valproate is well tolerated in unstable patients with status epilepticus
87. Placebo-controlled study of divalproex sodium for agitation in dementia
88. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: Results of double-blind, placebo-controlled trial
89. The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances
90. Valproic acid treatment of agitation in dementia
91. An open trial of valproate for agitation in geriatric neuropsychiatric disorders
92. Divalproex: A possible treatment alternative for demented, elderly aggressive patients
93. Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic
94. Valproate in the treatment of behavioral agitation in elderly patients with dementia
95. Valproic acid for physically aggressive behavior in geriatric patients
96. Divalproex sodium in the treatment of aggressive behaviour and dysphoria in patients with organic brain syndromes
97. The effects of sodium valproate on disturbed behavior in dementia
98. Sodium valproate in the treatment of behavioral disturbance in dementia
99. Withdrawal from controlled carbamazepine therapy followed by further carbamazepine treatment in patients with dementia
100. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia
101. Carbamazepine use in aggressive behavior associated with senile dementia
102. Effect of carbamazepine on agitation in Alzheimer's disease in patients refractory to neuroleptics
103. Carbamazepine treatment of agitation in nursing home patients with dementia: A preliminary study
104. Comparison of carbamazepine and trazodone in the control of aggression/agitation in demented, institutionalized patients: A randomized double blind parallel study [abstr]
105. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics
106. Carbamazepine for aggressive agitation in demented patients during nursing care
107. A preliminary study of carbamazepine in the treatment of assaultive patients with dementia
108. Carbamazepine treatment of agitation associated with dementia
109. Carbamazepine in senile dementia and overactivity - A placebo controlled double blind trial
110. Effectiveness of gabapentin for the treatment of behavioral disorders in dementia
111. Gabapentin in geriatric psychiatry patients
112. Gabapentin for disruptive behavior in an elderly demented patient
113. Gabapentin for behavioral agitation in Alzheimer's disease
114. Effect of zonisamide on disturbed behavior in Alzheimer's disease
115. Case report of zonisamide treatment for aggression associated with Alzheimer's disease
116. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia
117. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial
118. Epidemiology, etiology, and treatment of geriatric mania
119. Lithium toxicity in the elderly
120. Anticonvulsants in bipolar elderly
121. Efficacy of lithium vs. valproate in the treatment of mania in the elderly: A retrospective study
122. Divalproex for the treatment of geriatric bipolar disorder
123. Safety and efficacy of divalproex sodium in elderly bipolar patients
124. Divalproate augmentation in lithium-resistant, rapid cycling mania in four geriatric patients
125. Tolerability of divalproex sodium in elderly psychiatric patients with mixed diagnoses
126. Valproate use in the older manic patient
127. Divalproex treatment of mania in elderly patients
128. Parenteral valproate for control of acute mania
129. The use of valproate in an elderly population with affective symptoms
130. Carbamazepine for treatment-resistant melancholia
131. Senile tremor. What is the prevalence and severity of tremor in older adults?
132. Essential tremor
133. Acute and chronic effects of propranolol and primidone in essential tremor
134. A randomized placebo-controlled trial of gabapentin and propranolol in essential tremor
135. Double-blind placebo controlled study of gabapentin in essential tremor
136. Gabapentin for treatment of pain and tremor: A large case series
137. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): Double-blind crossover trial
138. Tegretol in the treatment of diabetic neuropathy
139. Double-blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy
140. Carbamazepine in the treatment of neuralgia: Use and side effects
141. Diabetic peripheral neuropathy: Nerve conduction studies before, during and after carbamazepine therapy
142. Antiepileptic drugs: A review of clinically significant drug interactions
143. Clinical trial of carbazepine (Tegretol) in trigeminal neuralgia
144. Adjuvant analgesics in pain management
145. Population pharmacokinetics of carbamazepine in adults with epilepsy
146. Analgesic drugs for neuropathic and sympathetically maintained pain
147. Neuropathic pain
148. Painful polyneuropathy: Diagnosis, pathophysiology, and management
149. Phenytoin in the treatment of diabetic symmetrical polyneuropathy
150. Phenytoin in the treatment of trigeminal and other neuralgias
151. Age and phenytoin kinetics in adult epileptics
152. Gabapentin monotherapy for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. A randomized controlled trial
153. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy
154. Gabapentin for the treatment of postherpetic neuralgia. A randomized controlled trial
155. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia
156. Studies on the concomitant use of carbamazepine and clomipramine for the relief of post-herpetic neuralgia
157. The management of postherpetic pain using sodium valproate and amitriptyline
158. The medical and surgical management of trigeminal neuralgia
159. Tic douloureux treated with new anticonvulsant
160. Long-term treatment of trigeminal neuralgia with carbamazepine
161. Neuropathic pain of peripheral origin: Advances in pharmacological treatment
162. Central post-stroke pain - A controlled trial of amitriptyline and carbamazepine
163. Gabapentin for treatment of thalamic pain syndrome
164. Lamotrigine control of central pain
165. Anticonvulsant drugs for management of pain: A systematic review
166. Pharmacy-based adverse drug reaction monitoring program
167. Phenytoin toxicity in an older patient with slow metabolism and atypical presentation
168. Clinical pharmacology of antiepileptic drugs: Selected topics
169. Illness presentation in elderly patients
170. Reduced serum albumin concentrations in elderly patients: A report from the Boston collaborative surveillance program
171. Plasma protein binding of drugs in elderly patients
172. Effect of age and sex on the plasma binding of acidic and basic drugs
173. Changes in drug metabolism with increasing age. II. Phenytoin clearance and protein binding
174. Influence of protein binding and use of unbound (free) drug concentrations
175. Pharmacokinetic pitfalls of present antiepileptic medications
176. Oxidative metabolism of hexobarbital in human liver: Relationship to polymorphic S-mephenytoin 4-hydroxylation
177. Effect of age on single and multiple dose pharmacokinetics of erythromycin
178. Age related changes in the pharmacokinetics and pharmacodynamics of nifedipine
179. Aging and drug interactions. III. Individual and combined effects of cimetidine and cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers
180. Age associated stereoselective alterations in hexobarbital metabolism
181. The effects of age and liver disease on the disposition and elimination of diazepam in adult man
182. Cognitive side-effects of chronic antiepileptic drug treatment: A review of 25 years of research
183. Impact of valproate and phenytoin on cognitive function in elderly patients: Results of a single-blind randomized comparative study
184. Cognitive effects of anticonvulsant monotherapy in elderly patients: A placebo-controlled study
185. Results of a nation-wide Veterans Administration cooperative study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone
186. Effect of valproate on cognitive functioning. Comparison with carbamazepine
187. Adverse events (AEs) when topiramate is titrated to effect: Results from an open-label, in-practice study with 800+ patients
188. Cognitive and behavioral effects of antiepileptic drugs
189. Epilepsy, anticonvulsant drugs and cognition
190. Association of race and other potential risk factors with nonvertebral fractures in community-dwelling elderly women
191. Case-control study and sequelae of symptomatic vertebral fractures in men
192. Risk factors for hip fracture in white women
193. Falls related to vitamin D and parathyroid hormone in an Australian nursing home and hostel
194. Seizures and epilepsy in the elderly
195. Bone density and antiepileptic drugs: A case-controlled study
196. Bone mineral content in epileptics
197. Anticonvulsant drugs and bone metabolism
198. Bone mineral density measured by dual-energy absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs
199. Long-term anticonvulsant therapy leads to low bone mineral density: Evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells
200. Study of osteoporotic fractures research group. Factors associated with appendicular bone mass in older women
201. Strategies to protect bone mass in the older patient with epilepsy
202. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment
203. Serum vitamin D metabolites in epileptic patients treated with 2 different anti-convulsants
204. Effect of carbamazepine and valproate on bone mineral density
205. Biotransformation, general principles
206. Bone marrow, cytokines, and bone remodeling
207. Overview of the safety of newer antiepileptic drugs
208. Pharmacokinetics of tiagabine. A gamma-aminobutyric acid-uptake inhibitor in healthy subjects after single and multiple doses
209. Osteoporosis prevention, diagnosis, and therapy
210. The new anti-convulsant drugs: Implications for avoidance of adverse effects
211. A mechanistic approach to antiepileptic drug interactions
212. Variability of serum phenytoin concentrations in nursing home patients
213. A multiple-dose safety and bioequivalence study of a narrow therapeutic index drug: A case for carbamazepine
214. Plasma protein binding of drugs as a function of age in adult human subjects
215. Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia
216. Antipyrine metabolism in man: Influence of age, alcohol, caffeine and smoking
217. Disposition of antipyrine and phenytoin correlated with age and liver volume in man
218. Phenytoin and serum phenytoin variability among patients in a long-term care facility
219. Pattern of dental caries in an adult rural population
220. Interference of oral phenytoin absorption by continuous nasogastric feedings
221. Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings
222. Antiepileptic drugs and alpha 1-acid glycoprotein
223. Clinical pharmacokinetic considerations in the elderly; an update
224. The effects of age on carbamazepine pharmacokinetics and adverse effects
225. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: A review
226. A rationale guide to routine blood monitoring in patients receiving antiepileptic drugs
227. Pharmacokinetic model to describe self-induced decreases in steady-state concentrations of carbamazepine
228. Bioavailability of rectally administered lorazepam
229. Biopharmaceutics of rectal administration of drugs in man. IX. Comparative biopharmaceutics of diazepam after single rectal, oral, intramuscular and intravenous administration
230. Variable free and total valproic acid concentrations in sole- and multidrug therapy
231. Valproic acid: In vitro plasma protein binding and interaction with phenytoin
232. Pharmacokinetics of valproic acid in the elderly
233. Valproic acid clearance: Unbound fraction and diurnal variation in young and elderly adults
234. Pharmacokinetics of valproic acid in young and elderly subjects
235. Apparent valproic acid neurotoxicity in a hypoalbuminemic patient
236. Valproate-associated pancreatitis
237. Factors influencing plasma phenobarbitone levels in epileptic patients
238. The disposition of primidone in elderly patients
239. Single and multiple dose pharmacokinetics of felbamate in the elderly
240. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma
241. Gabapentin
242. Gabapentin: Pharmacokinetics in subjects with various degrees of renal function
243. Effects of age and gender on single-dose pharmacokinetics of gabapentin
244. Changes in body weight with chronic, high-dose gabapentin therapy
245. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers
246. Lamotrigine: A review of its pharmacological properties and clinical efficacy in epilepsy
247. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers
248. Lamotrigine
249. The tolerability of lamotrigine in elderly patients with epilepsy
250. Pharmacokinetic profile of LEV: Towards ideal characteristics
251. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites
252. The influence of age on the antiepileptic agent oxcarbazepine
253. Therapeutic experience with 947 epileptic out-patients in oxycarbazepine treatment
254. Two new drugs for epilepsy
255. Oxcarbazepine
256. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy
257. Oxcarbazepine: Double-blind, randomized, placebo-controlled, monotherapy trial for partial seizures
258. Oxcarbazepine-induced hyponatremia, a cross-sectional study
259. Hyponatremia during oxcarbazepine therapy
260. Oxcarbazepine does not affect the anticoagulant activity of warfarin
261. The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy
262. Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy
263. Tiagabine therapy for complex partial seizures. A dose frequency study
264. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function
265. Effect of renal impairment on the pharmacokinetics and safety of tiagabine
266. Tiagabine: The safety landscape
267. Safety of topiramate: Adverse events and relationships to dosing
268. An audit of topiramate use in a general neurology clinic
269. Investigation of the mechanistic basis of topiramate-associated nephrolithiasis of urinary and serum constituents
270. Pharmacokinetics of zonisamide in young and elderly subjects
271. Important pharmacokinetic properties of antiepileptic drugs
272. New opportunities for the treatment of epilepsy
273. The cost of epilepsy in the United Kingdom: An estimation based on the results of two population-based studies